Atopic dermatitis: lebrikizumab shows efficacy in phase 2b trial

  • Guttman-Yassky E & al.
  • JAMA Dermatol
  • 26/02/2020

  • Brian Richardson, PhD
  • Clinical Essentials
L'accesso ai contenuti di questo sito è riservato agli operatori del settore sanitario italiano L'accesso ai contenuti di questo sito è riservato agli operatori del settore sanitario italiano

Takeaway

  • Lebrikizumab, an anti-IL-13 monoclonal antibody, is associated with clinical improvements in patients with atopic dermatitis, according to results from a phase 2b trial.

Why this matters

  • Lebrikizumab may represent a potentially useful new treatment option if these results are replicated in phase 3 trials.

Key results

  • Lebrikizumab was associated with greater improvements in the Eczema Area and Severity Index compared with placebo.
    • −41.1% for placebo.
    • −62.3% for lebrikizumab 125 mg every 4 weeks (P=.02 vs placebo).
    • −69.2% for lebrikizumab 250 mg every 4 weeks (P=.002 vs placebo).
    • −72.1% for lebrikizumab 250 mg every 2 weeks (P<.001 vs placebo>
  • Treatment-emergent adverse events were reported in:
    • 46.2% of patients who received placebo,
    • 57.5% of patients who received lebrikizumab 125 mg every 4 weeks,
    • 48.8% of patients who received lebrikizumab 250 mg every 4 weeks, and
    • 61.3% of patients who received lebrikizumab 250 mg every 2 weeks.

Study design

  • 280 patients with atopic dermatitis were randomly allocated to placebo (n=52) or lebrikizumab 125 mg every 4 weeks (n=73), 250 mg every 4 weeks (n=80), or 250 mg every 2 weeks (n=75).
  • Funding: Dermira, Inc.

Limitations

  • Relatively small treatment groups.